<- Go Home

Akili, Inc.

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts. As of July 2, 2024, Akili, Inc. operates as a subsidiary of Virtual Therapeutics Corp.

Market Cap

$34.0M

Volume

753.0K

Cash and Equivalents

$63.2M

EBITDA

-$55.9M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$1.1M

Profit Margin

56.11%

52 Week High

$1.25

52 Week Low

$0.19

Dividend

N/A

Price / Book Value

0.68

Price / Earnings

-0.70

Price / Tangible Book Value

0.68

Enterprise Value

-$15.6M

Enterprise Value / EBITDA

0.28

Operating Income

-$56.2M

Return on Equity

68.06%

Return on Assets

-36.62

Cash and Short Term Investments

$63.2M

Debt

$13.6M

Equity

$50.2M

Revenue

$1.9M

Unlevered FCF

-$29.2M

Sector

Health Care Technology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches